Business
Board Changes
Board Changes.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 7143V hVIVO plc 20 April 2016 \n\nFor immediate release 07:01: 20 April 2016\n \nHVIVO PLC\n(\"hVIVO\" or the \"Company\")\n \nBOARD CHANGES\n \nhVIVO plc (AIM: HVO), the pioneer of human disease models, is pleased to announce changes to its Board to support hVIVO's continued growth and evolution. David Norwood, who was appointed Chairman of the Board in 2011 and served in that capacity until 2014, will be retiring as a Non-Executive Director by rotation at the Company's AGM on 23 May 2016 and not seeking reappointment. Alison Fielding, who has served as a Non-Executive Director of hVIVO since July 2014, will also be retiring at the Company's AGM. Mark Warne joins the hVIVO Board as a Non-Executive Director with immediate effect and which will be proposed for approval at the Company's AGM. \n \nBoth David and Alison have provided invaluable guidance to hVIVO since they joined. While David Norwood is retiring as a Director, he will continue to support hVIVO as a strategic consultant. David has played a pivotal role in crafting the hVIVO vision and business strategy since 2011, along with providing stewardship as a Director. In his new role as a consultant to hVIVO, he will continue to support hVIVO in the development of our strategy and investor relations. Alison has provided valuable experience building high performance companies and has helped to steer hVIVO's evolution into a more products-based organisation.\n \nMark brings a wealth of technology commercialisation experience to help direct hVIVO through its next chapter of product development and value creation. He is Head of IP Group plc's Healthcare division, which at the end of December 2015 had shareholdings in 31 companies valued at over £275 million. He represents IP Group plc on the boards of a number of its portfolio companies, both quoted and private. Mark has been at IP Group since 2008 and has extensive experience in building world-changing healthcare businesses as well as in managing transactions including portfolio company IPOs, financings and M&A. \n \nKym Denny, Chief Executive Officer, commented, \"hVIVO is moving quickly to broaden its platform and commercialise its discoveries. The changes to our Board enable us to continue th...